x

Posted 27 April, 2022

Y-mAbs Therapeutics, Inc. appointed Thomas Gad as new CEO

Nasdaq:YMAB appointed new Chief Executive Officer Thomas Gad in a 8-K filed on 27 April, 2022.


  In addition, on April 22, 2022, the Company's Board of Directors appointed Thomas Gad, the Company's Founder, Chairman, President and Head of Business Development & Strategy, to act as its Interim Chief Executive Officer effective immediately.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Y-mAbs Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Market Cap
$219M
View Company Details
Y-mAbs Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On April 27, 2022, Y-mAbs Therapeutics Inc. (the "Company"), announced certain executive management changes. Effective April 22, 2022, Dr. Claus Moller stepped down from his positions as Chief Executive Officer and as a member of the Company's Board of Directors. There were no disagreements with the Company expressed by Dr. Møller on any matter relating the Company's operations, policies or practices.


The Company wants to thank Dr. Møller for his service and many accomplishments during his tenure as Company's Chief Executive Officer and wishes him the very best.


In addition, on April 22, 2022, the Company's Board of Directors appointed Thomas Gad, the Company's Founder, Chairman, President and Head of Business Development & Strategy, to act as its Interim Chief Executive Officer effective immediately. At the same time, Mr. Gad stepped down as Chairman of the Board of Directors and the Company's Board of Directors appointed Dr. James I. Healy as its new Chairman effective immediately.